Hosted on MSN1h
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
Medscape10h
Trastuzumab Emtansine Ups Long-term Survival in HER2-Positive Breast Cancer
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
GlobalData on MSN10h
OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients
The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...
Healio13h
Adjuvant regimen extends survival in early HER2-positive breast cancer
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...
OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy
Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...
FierceBiotech1d
OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients
The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial
OS Therapies (OSTX) up 65% in premarket trading after positive phase 2b data on OST-HER2 for lung metastatic osteosarcoma ...
The American Journal of Managed Care4h
Innovations in Breast Cancer Treatment With Dr Dawn Klemow
Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.